Perspective · 31 Oct 2024
Conference abstractPublished 23 Nov 2012
Development of new anticancer agents
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cancer continues to be a major health concern and a number of deaths are caused by cancer that is second only to cardiovascular diseases. The development of compounds that target genes involved in cancer pathogenesis is a potential area of cancer drug discovery. A number of anticancer drugs employed clinically exert their effect by inhibiting nucleic acid (DNA or RNA) or protein synthesis. It is evident that DNA is an important cellular target for many anticancer agents. Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are naturally occurring compounds isolated from various Streptomyces species. The PBDs exert their biological activity through covalent binding within the minor groove of DNA. Several PBD conjugates have been synthesized to investigate the detailed biological aspects relating to the mechanism of action. Some of the potent molecules like PBD-quinazolinones and PBD-diaryloxadiazoles have been evaluated for their in vivo efficacy studies. These studies suggest that such PBD conjugates have promising anticancer activity. Some of the PBD conjugates act as activators of p53 and suppressors of NF-κB and thereby they could be considered as promising anticancer agents with improved potential for the suppression of tumours. To improve the selectivity as well as stability, some new β-galactoside prodrugs of PBDs have been synthesized and evaluated for their potential use in selective therapy of solid tumors by ADEPT and PMT protocols. Another important property of these molecules is their enhanced water solubility and stability, which are essential for a molecule to be an effective drug.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 26 Aug 2024
Pharmacokinetic Interactions of New-Generation Anticancer Agents: Insights and Implications
Article · 1 Feb 2024
Targeting Novel Pathways: Investigating the Therapeutic Potential of a New Class of Anticancer Agents
Conference abstract · 10 Oct 2020
Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b] indole Derivatives as Broad-Spectrum Potent Anticancer Agents
Research article · 23 May 2019
Design, Synthesis and Molecular Modeling of New 1,3,5-Triazine Derivatives as Anticancer Agents
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ahmed Kamal”

